Mustang Bio Inc (MBIO)
NASDAQ:MBIO
MBIO Stock Chart & Stats
$1.09
-$0.01(-4.59%)
At close: 4:00 PM EST
$1.09
-$0.01(-4.59%)
Day’s Range― - ―
52-Week Range$0.53 - $7.00
Previous CloseN/A
Volume2.68M
Average Volume (3M)94.14K
Market Cap
$5.61M
Enterprise Value-$11.66M
Total Cash (Recent Filing)$17.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,732,092
10 Day Avg. Volume88,215
30 Day Avg. Volume94,141
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-9.15
Enterprise Value/Market Cap-2.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit284.36
Enterprise Value/Ebitda5.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnThe company has materially reduced cash burn over multiple years, indicating tighter cost discipline and a smaller ongoing funding gap. That trend lengthens runway and reduces near-term financing frequency risk, improving the sustainability of development programs over the next several quarters.
Low Leverage / No DebtHaving no recorded debt reduces bankruptcy and interest burden risk and preserves optionality for strategic financings or partnerships. This clean capital structure supports flexibility in executing clinical programs without immediate fixed-charge pressure on cash flows.
Specialized Clinical-stage Cell & Gene Therapy FocusA focused cell and gene therapy pipeline targets high-barrier, underserved markets where successful trials can yield durable competitive advantages, regulatory exclusivity and high commercial value. The specialized expertise and assets provide strategic optionality for partners or acquirers.
Bears Say
No Revenue / Negative Free Cash FlowThe company remains pre-commercial with no product sales and persistent negative operating cash flows. That structural absence of operating revenue means continued dependency on external capital to fund R&D, limiting long-term self-sufficiency until regulatory approval and commercialization occur.
Reliance On External Funding And Dilution RiskExpanded share pools and prior financing dependence highlight an ongoing need to raise capital through equity, which dilutes holders and can compress per-share economics. Reliance on episodic financings increases execution risk if markets or partner deals are delayed.
Small Asset Base And Historical Financial VolatilityTotal assets have fallen and equity levels have swung, including periods of negative equity and high leverage historically. This indicates past financial stress and a smaller operating base, which can constrain scalability and heighten vulnerability to setbacks in trial programs or financing timelines.
Mustang Bio News
MBIO FAQ
What was Mustang Bio Inc’s price range in the past 12 months?
Mustang Bio Inc lowest stock price was $0.53 and its highest was $7.00 in the past 12 months.
What is Mustang Bio Inc’s market cap?
Mustang Bio Inc’s market cap is $5.61M.
When is Mustang Bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mustang Bio Inc’s earnings last quarter?
Currently, no data Available
Is Mustang Bio Inc overvalued?
According to Wall Street analysts Mustang Bio Inc’s price is currently Overvalued.
Does Mustang Bio Inc pay dividends?
Mustang Bio Inc does not currently pay dividends.
What is Mustang Bio Inc’s EPS estimate?
Mustang Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio Inc have?
Mustang Bio Inc has 6,732,092 shares outstanding.
What happened to Mustang Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mustang Bio Inc?
Currently, no hedge funds are holding shares in MBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Silexion Therapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
8.35% Insiders
0.97% Mutual Funds
1.35% Other Institutional Investors
88.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---